Bromodomain-containing protein 9 (BRD9) belonging to the BRD family, a major constituent of the SWI/SNF chromatin remodeling complex named non-canonical BAF, has been identified as a novel therapeutic target in AML [12,13]. The gene discussed is BRD9; the disease is acute myeloid leukemia.